Testing Of Asymptomatic Patients Research Articles

The usefulness of QT interval measurement as a screening tool for cascade testing in asymptomatic patients at risk of long QT syndrome

Abstract Background Long QT syndrome (LQTS), an inherited arrhythmic syndrome, remains a public health concern with up to 3000 unexpected deaths in the US annually. A simple 12-lead ECG is the most easily accessible tool for initial screening. Purpose To describe the diagnostic utility of the standard QT correction techniques in 12-Lead ECGs, in a screening population of first-degree relatives of persons with LQTS of known genotype. Methods In this single centre study, data were included on consecutive patients undergoing cascade clinical and genetic testing for LQTS, who had a first degree relative with genotype-positive LQTS, from the years 2019 to 2022. Patient demographics, baseline ECG and genetic results were obtained. The QT interval was manually calculated between three independent readers using the tangent method and corrected using the 4 most commonly used formulae: Bazett (BQTc), Fridericia (FreQTc), Framingham (FraQTc) and Hodges (HQTc). The Mean QT was calculated by taking the average of four consecutive QT measurements in lead II or V5. The QT dispersion (QTd), was also calculated by using the formula: QTd = QT max – QT min. Results Data was available on 97 patients from 14 families. The mean age at screening was 44 years, and 51.5% were males. Two-thirds of patients were asymptomatic (n = 74, 76.3%). Fifteen patients had syncopal events. 72.2% (n = 70) of patients had a family history of arrhythmic death. After clinical screening and genotyping, 46.4% (n = 45) patients were gene positive for either KCNQ1 (75.5%) or KCNH2 (24.5%). Patients with prior syncope were more likely to be gene positive (72.7% vs 39.2%, p = 0.005). The 12-Lead ECG derived QTc result is listed in Table 1, with all correction modalities showing a higher corrected QT in the genotype-positive group (p <0.001). The diagnostic performance of BQTc was similar to that of the newer formulae (FreQTc, FraQTc and HQTc) when correcting for heart rate within the range of 60 – 100bpm as listed in Table 2. At a cut-off value of 440ms, BQTc formula had a sensitivity of 51% and a specificity of 84% for predicting genotype pathogenicity as listed in Table 3. The QT dispersion was higher in patients with KCNH2 compared to those with KCNQ1 (122msec, SD 30.5 vs 74.2 msec, SD 30.4, p value <0.001). Patients with KCNH2 were more likely to require an ICD (83.3% vs 16.7%, p <0.001). The mean Schwartz score in gene positive patient was 2.6 compared to 1.9 (p <0.003). Conclusion Formula correction of QT interval to heart rate had good overall diagnostic performance. Both FreQT and FraQT had high AUROC across different heart rates, though there was no statistically significant difference seen between correction formulae. The ECG remains a good preliminary screening tool method for identifying patients with increased risk LQTS in this population. Larger studies are needed to power for comparisons between QT correction methods.

P09 Feasibility of retrospective chart review to assess alignment of urinary tract infection diagnosis, testing and treatment decisions with UKHSA diagnostic guidance in patients 65 years+ in the emergency department

Abstract Background UKHSA urinary tract infection (UTI) diagnostic guidance uses presence/absence of specific symptoms/signs to guide decisions on urine culture and antibiotic treatment.1 The goal is treatment of those with highest risk of infection, avoiding serious illness, whilst limiting antibiotic overuse. UK improvement initiatives2,3 encourage hospitals to align with UKHSA guidance. UTI is a common infection in the emergency department (ED) and diagnosis can be challenging in the elderly.4,5 Objectives To explore retrospective chart review to quantify UTI treatment alignment with UKHSA UTI guidance.1 Identify ED patients aged 65 years+ (65+) with primary diagnosis of UTI. Limit to non-admitted for manageable sample. Complete retrospective chart review to elicit documented UTI symptoms/signs and associated: (i) urine dipstick testing; (ii) urine sampling for microscopy, culture and susceptibility (MC&S); and (iii) antibiotic treatment. Assess alignment with relevant UKHSA guidance. Estimate time taken. Methods Electronic patient record search for key terms (Table 1) identified 6076 ED attendances 65+ between 1 August and 31 October 2021. Forty patients met inclusion criteria. Paramedic/ED notes were reviewed, and information gathered regarding presence/absence of: UTI symptoms/signs as per UKHSA guidelines;1 urine dipstick test; urine for MC&S; and UTI antibiotic treatment. Findings were mapped to illustrate if UKHSA diagnostic pathway and intended antibiotic prescribing decisions followed. Table 1.Key termsSearch termsSearch fieldsUrin, UTI, pyelonephritis, cystitis, urosepsis, CAUTI, AKI, Acute Kidney Injury, Flank painReason for visit, Chief Complaint, Presenting Complaint, ECDS Results Twenty-seven of 40 patients matched UKHSA criteria for lower UTI/pyelonephritis. Three of 27 followed recommended pathway of: no dipstick; urine for MC&S; and antibiotic. Twenty of 27 had urine dipstick test (not recommended); 16/27 had urine sample for MC&S (recommended); 26/27 received an antibiotic (recommended). Twenty-three who received antibiotics had dipstick testing, no urine for MC&S or both. One patient did not receive indicated antibiotic treatment. Documented symptoms/signs did not indicate UTI/pyelonephritis in 13/40 patients. Two of 13 followed the recommended pathway of: no dipstick; no urine for MC&S; and no antibiotic. Seven of 13 received a dipstick test; 6/13 had urine for MC&S; 9/13 received antibiotics which were not indicated. Five of 40 followed the recommended pathway; 30/40 received the recommended treatment. The time cost was around 30 min/patient. Conclusions UKHSA guideline alignment was low. Testing in asymptomatic patients appeared to result in unnecessary antibiotic use. Retrospective chart review generated detailed data to assess alignment, however results may represent poor documentation not poor alignment. Retrospective chart review time cost too high for large numbers and assumes accurate documentation.

Using CT radiomic features based on machine learning models to subtype adrenal adenoma

BackgroundFunctioning and non-functioning adrenocortical adenoma are two subtypes of benign adrenal adenoma, and their differential diagnosis is crucial. Current diagnostic procedures use an invasive method, adrenal venous sampling, for endocrinologic assessment.MethodsThis study proposes establishing an accurate differential model for subtyping adrenal adenoma using computed tomography (CT) radiomic features and machine learning (ML) methods. Dataset 1 (289 patients with adrenal adenoma) was collected to develop the models, and Dataset 2 (54 patients) was utilized for external validation. Cuboids containing the lesion were cropped from the non-contrast, arterial, and venous phase CT images, and 1,967 features were extracted from each cuboid. Ten discriminative features were selected from each phase or the combined phases. Random forest, support vector machine, logistic regression (LR), Gradient Boosting Machine, and eXtreme Gradient Boosting were used to establish prediction models.ResultsThe highest accuracies were 72.7%, 72.7%, and 76.1% in the arterial, venous, and non-contrast phases, respectively, when using radiomic features alone with the ML classifier of LR. When features from the three CT phases were combined, the accuracy of LR reached 83.0%. After adding clinical information, the area under the receiver operating characteristic curve increased for all the machine learning methods except for LR. In Dataset 2, the accuracy of LR was the highest, reaching 77.8%.ConclusionThe radiomic features of the lesion in three-phase CT images can potentially suggest the functioning or non-functioning nature of adrenal adenoma. The resulting radiomic models can be a non-invasive, low-cost, and rapid method of minimizing unnecessary testing in asymptomatic patients with incidentally discovered adrenal adenoma.

Exercise Testing in Aortic Stenosis: Safety, Tolerability, Clinical Benefits and Prognostic Value.

Background: Routine exercise testing in asymptomatic patients with valvular heart disease (VHD) better classifies the hemodynamic severity of valve stenosis or regurgitation, and describes the symptomatic status and functional capacity of the patient. This is crucial for planned surveillance and optimal timing of surgery, particularly for aortic stenosis (AS), because once symptoms occur, there is a sharp increase in the risk of sudden death unless valve intervention is performed. Purpose: To conduct a focused clinical review on the benefits of exercise testing in patients with AS. Methods: The electronic database PubMed was systematically searched for relevant retrospective and prospective cohort studies reporting on the safety, feasibility and tolerability of exercise testing in VHD, with a special focus on AS. Results and conclusions: In patients with significant AS, exercise testing is safe, feasible and reveals symptoms in a significant proportion of patients. In addition, serial testing has incremental prognostic value over a baseline test alone. Exercise testing in patients with AS is underused and should be performed routinely to refine the hemodynamic severity of AS.

Meta-analysis of COVID-19 prevalence during preoperative COVID-19 screening in asymptomatic patients

ObjectivesPatients with COVID-19 may be asymptomatic and are able to transmit COVID-19 during a surgical procedure, resulting in increased pressure on healthcare and reduced control of COVID-19 spread. There remains...

Exercise Electrocardiogram Testing in Asymptomatic Patients with Diabetes and Left Ventricular Diastolic Dysfunction

Objectives: The main objective of the study is to find the exercise electrocardiogram testing in asymptomatic patient with Type-II diabetes and left ventricular diastolic dysfunction.
 Materials and Methods: This descriptive study was conducted Fatima Jinnah Hospital, Lahore during January 2019 to November 2019. The data was collected from 50 patients of type II DM. These all patients has normal electrocardiogram (ECG) and normal systolic function. 
 Results: The data was collected from 50 patients of both genders. The mean age of the patients was 47.83±5.61 years. After getting data the results were divided into two parts. There were 25 patients in group A and 25 patients group B. The mean duration of diabetes is 2.5±5.61 years. There were 20 males and 30 females in this data. There were no significant difference of fasting blood sugar in both groups. There was no statically significant difference between two groups regarding left atrial dimension, aortic root dimension, LV end-diastolic dimension, ejection and LV mass.
 Conclusion: It is concluded that It is concluded that coronary supply route sicknesses is a typical issue in DM, with diastolic brokenness and increment uniquely in patients with positive pressure practice electrocardiography.

Performance of SARS-CoV-2 antigen testing in symptomatic and asymptomatic adults: a single-center evaluation

BackgroundAntigen testing offers rapid and inexpensive testing for SARS-CoV-2 but concerns regarding performance, especially sensitivity, remain. Limited data exists for use of antigen testing in asymptomatic patients; thus, performance and reliability of antigen testing remains unclear.Methods148 symptomatic and 144 asymptomatic adults were included. A nasal swab was collected for testing by Quidel Sofia SARS IFA (Sofia) as point of care. A nasopharyngeal swab was also collected and transported to the laboratory for testing by Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV RT-PCR (Cepheid).ResultsOverall, Sofia had good agreement with Cepheid (> 95%) in adults, however was less sensitive. Sofia had a sensitivity of 87.8% and 33.3% for symptomatic and asymptomatic patients, respectively. Among symptomatic patients, testing > 5 days post symptom onset resulted in lower sensitivity (82%) when compared with testing within 5 days of symptom onset (90%). Of the four Sofia false-negative results in the asymptomatic cohort, 50% went on to develop COVID-19 disease within 5 days of testing. Specificity in both symptomatic and asymptomatic cohorts was 100%.ConclusionsSofia has acceptable performance in symptomatic adults when tested < 5 days of symptom onset. Caution should be taken when testing patients with ≥ 5 days of symptoms. The combination of low prevalence and reduced sensitivity results in relatively poor performance of in asymptomatic patients. NAAT-based diagnostic assays should be considered in when antigen testing is unreliable, particularly in symptomatic patients with > 5 days of symptom onset and asymptomatic patients.

Prognostic Value of Cardiovascular Testing in Asymptomatic Patients With a History of Cardiovascular Disease: A Review of Contemporary Medical Literature.

The cardiac stress testing, carotid duplex, coronary artery calcium (CAC) scoring, myocardial perfusion imaging, coronary angiography, C-reactive protein (CRP), glycated hemoglobin (HbA1C), total serum cholesterol, duplex ultrasonography, digital subtraction angiography, magnetic resonance angiography (MRA), computed tomography angiography (CTA), digital subtraction angiography, and ankle-brachial index (ABI) independently predict the risks and prognostic outcomes in asymptomatic cardiovascular disease (CVD) patients. The peripheral artery disease (PAD) screening guides the diagnosis, management, and prognosis of hemodynamically significant arterial stenosis, calcification, and malignant hypertension in patients with CVD without symptoms. The 79% sensitivity and 96% specificity of ABI screening, 90% sensitivity and 97% specificity of MRA, and 95% sensitivity and 50% specificity of CTA for tracking arterial occlusion indicate the high prognostic value of these tests in the setting of CVD. The 85% specificity and 60-70% sensitivity of cardiac stress testing substantiate its suitability to determine asymptomatic CVD prognosis related to myocardial ischemia, heart failure, multivessel disease, and unstable angina. The carotid duplex ultrasound potentially identifies long-term mortality, stroke, atherosclerosis, plaque instability, and angiographic stenosis among asymptomatic CVD patients with 94% specificity and 90% sensitivity. The CAC scoring has a positive predictive value (PPV) of 45.7% for identifying aortic valve calcium and PPV of 79.3% for tracking thoracic artery calcium. The medical literature provides substantial evidence concerning the validity, reliability, and prognostic value of cardiovascular testing for asymptomatic patients. Future studies are needed to undertake detailed assessments of benefits versus adverse outcomes associated with the prospective scaling (of cardiovascular testing) across asymptomatic CVD patients.

Utility of Mass SARS-CoV-2 Testing of Asymptomatic Patients Before Ambulatory and Inpatient Preplanned Procedures Requiring Moderate Sedation or General Anesthesia

Utility of Mass SARS-CoV-2 Testing of Asymptomatic Patients Before Ambulatory and Inpatient Preplanned Procedures Requiring Moderate Sedation or General Anesthesia

Aerosol Generation During Peak Flow Testing: Clinical Implications for COVID-19.

Peak flow testing is a common procedure performed in ambulatory care. There are currently no data regarding aerosol generation during this procedure. Given the ongoing debate regarding the potential for aerosol transmission of SARS-CoV-2, we aimed to quantify and characterize aerosol generation during peak flow testing. Five healthy volunteers performed peak flow maneuvers in a particle-free laboratory space. Two devices continuously sampled the ambient air during the procedure. One device can detect ultrafine particles 0.02-1 μm in diameter, while the second device can detect particles 0.3, 0.5, 1.0, 2.0, 5.0, and 10 μm in diameter. Five different peak flow meters were compared to ambient baseline during masked and unmasked tidal breathing. Ultrafine particles (0.02-1 μm) were generated during peak flow measurement. There was no significant difference in ultrafine particle mean concentration between peak flow meters (P = .23): Respironics (1.25 ± 0.47 particles/mL), Philips (3.06 ± 1.22), Clement Clarke (3.55 ± 1.22 particles/mL), Respironics Low Range (3.50 ± 1.52 particles/mL), and Monaghan (3.78 ± 1.31 particles/mL). Ultrafine particle mean concentration with peak flow testing was significantly higher than masked (0.22 ± 0.29 particles/mL) and unmasked tidal breathing (0.15 ± 0.18 particles/mL, P = .01), but the ultrafine particle concentrations were small compared to ambient particle concentrations in a pulmonary function testing room (89.9 ± 8.95 particles/mL). In this study, aerosol generation was present during peak flow testing, but concentrations were small compared to the background particle concentration in the ambient clinical environment. Surgical masks and eye protection are likely sufficient infection control measures during peak expiratory flow testing in asymptomatic patients with well controlled respiratory symptoms, but COVID-19 testing remains prudent in patients with acute respiratory symptoms prior to evaluation and peak expiratory flow assessment while the community prevalence of SARS-CoV-2 cases remains high.

The incidence of occult endocrinopathies in patients with cancer undergoing immunotherapy in community practice.

e14571 Background: Immune checkpoint blockade (IO) can induce inflammation of the pituitary, thyroid or adrenal glands. This usually results in non-specific symptoms such as headache, low-energy, nausea and vomiting, which can be difficult to differentiate from symptoms associated with cancer and therapy-related symptoms. Therefore, the exact incidence of endocrinopathies is exceedingly difficult to estimate in community practices. Also, the variable methods of assessment, diagnosis, and monitoring used in different clinical trials make it challenging to precisely measure the incidence of endocrinopathies. Methods: This is a single-center retrospective chart review of patients diagnosed with cancer receiving immunotherapy for cancer treatment who had routine hormone levels checked during their treatment. Data collected includes tumor types and the types of IO agents used. Laboratory data collected included thyroid-stimulating hormone (TSH), testosterone level, follicular stimulating hormone (FSH), luteinizing hormone (LH), cortisol levels. Results: In total, 75 patients were included in the study. The primary indication for IO was lung cancer in 43 patients (57%), genitourinary tumors (12%), melanoma (12%) and head &amp; neck cancers (5.3%). Single-agent nivolumab (39 patients) was the most common IO agent used followed by single-agent pembrolizumab (22 patients), ipilimumab (11 patients), atezolizumab (3 patients), avelumab (1 patient) (There was one patient who got nivolumab initially and then pembrolizumab). Nine patients were treated with ipilimumab/nivolumab combination. The mean number of cycles received was 9.1. The total number of patients who developed at least one abnormal hormone level was 57(76%), with 33 out of 74 (45%) patients had at least one abnormal TSH, 29 out of 44 (66%) patients had at least one abnormal testosterone level, 10 out of 49 (20.4%) patients had at least one abnormal FSH and/or LH level, 36 out of 52 (69%) patients had at least one abnormal cortisol level. The mean number of days from starting IO to develop the first abnormal laboratory result was 106 days. Conclusions: The incidence of endocrinopathy was significantly high in patients receiving IO in this study, which is higher than what is reported in previous clinical trials. This could be due to frequent testing in asymptomatic patients and strict laboratory cut-off values which is not always clinically meaningful. This finding may highlight the importance of routine monitoring of the endocrine function during IO treatment. Routine measurement of hormone levels can detect asymptomatic endocrinopathy which may warrant further work-up and treatment. These findings should be validated in a larger prospective study.

Neurosurgery resumption in Wuhan during the early post-epidemic period: what should we pay attention to?

COVID-19 has spread globally, causing a pandemic and medical interruptions. As more countries control the epidemic, the resumption of work is imperative. However, asymptomatic carriers become the main source of infection. After several months of recovery, Wuhan had much experience with facing the challenge of work resumption. The purpose of this study was to investigate the safety of the resumption strategies, as well as the outcome of the resumption efforts, in the early post-epidemic period. A retrospective study was conducted in patients admitted between April 8 and June 30 to the neurosurgery department of Tongji Hospital, Wuhan. The medical information, past medical history, COVID-19 tests, laboratory parameters, CT results, and management were reviewed and recorded. 768 patients were admitted to the neurosurgery department at Tongji Hospital, and none of them became new infections. Our department recovered to 70% efficiency one month after the resumption of work. Two patients were found to have asymptomatic infections in the outpatient department. Two patients who recovered from COVID-19 underwent the surgery without recurrence of COVID-19. Tumor patients accounted for more than 50% of the surgery patients in the early period. It is feasible and helpful to follow our strict admission algorithm in the early post-epidemic period, even though the challenges of asymptomatic infectors exist. Two COVID-19 tests in 3 days are suggested within the early period. Protective downgrades should be based on the testing of asymptomatic patients in the area. Recovered COVID-19 patients can undergo surgery without recurrence.

Coronavirus Disease (COVID-19) Testing in Asymptomatic Patients Planned for Day Care Systemic Therapy: A Tertiary Cancer Center Experience

Abstract Introduction The Indian Council of Medical Research recommends coronavirus disease 2019 (COVID-19) testing for asymptomatic patients only in hospitalized condition or those seeking hospitalization for chemotherapy. Materials and Methods This was a retrospective study to assess the incidence of asymptomatic COVID-19 positivity among asymptomatic, adult patients who were planned for systemic therapy as day care at a tertiary care cancer center. COVID-19 testing was done by reverse transcriptase-polymerase chain reaction by throat/nasopharyngeal swab once before the first cycle of systemic therapy and once every 3 weeks until completion of systemic therapy. Results A total of 824 systemic therapies were delivered in day care from May 7 to June 20, 2020. Among the 761 COVID-19 testing done before systemic therapy, 11 patients were COVID-19 positive (1.45%, 95% confidence interval: 0.60–2.29). Among the 11 patients, 45% were negative before the first systemic therapy but tested positive before subsequent cycles. Among the asymptomatic COVID-19-positive patients, 54% were hospitalized for observation and 46% were on home quarantine for 14 days. None of them received investigational therapy or traditional treatment for COVID-19. None of the patients needed admission in the intensive care unit or oxygen/ventilatory support. There was no mortality among these patients. All patients turned COVID-19 negative at a median of 9 days. Currently, 45% (n = 5/11) of the patients have resumed systemic therapy. Conclusion The incidence of asymptomatic COVID-19 positivity among adult cancer patients planned for day care systemic therapy is low (1.45%). Hence, COVID-19 testing should be done after informed/shared decision with the patient/attendants. Repeat COVID-19 testing before each cycle of systemic therapy is preferable, as 45% of the patients were COVID-19 negative before the first cycle of systemic therapy and turned positive before subsequent cycles in the present study. There was no morbidity or mortality in this cohort of asymptomatic COVID-19-positive cancer patients.

SARS-CoV-2 Testing for Asymptomatic Patients with Cancer Prior and during Treatment: A Single Centre Experience.

Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC’s symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2.

462. Prevalence and Outcome of Asymptomatic Procedural Patients with COVID-19 Infection

BackgroundGuidelines recommend testing for SARS-COV-2 in asymptomatic individuals who are undergoing time-sensitive major surgery or aerosol generating procedures (AGPs) to guide infection prevention practices, including PPE use, and minimize risk of potential poor outcomes associated with COVID-19 infection by delaying the procedure in positive patients. However, evidence to support these recommendations are limited. We describe the outcome of asymptomatic patients with SARS-COV-2 undergoing surgery or AGPs.MethodsWe implemented a system-wide policy to test all patients requiring intubation or other AGPs at Henry Ford Health System (HFHS), a 5-hospital system in southeast Michigan. This was a retrospective review of asymptomatic surgical patients with COVID-19 infection between 5/1/2020–5/31/2020. All patients with positive polymerase chain reaction (PCR) of upper respiratory tract were included. Demographics, comorbidities, procedural/surgical categories, symptoms and outcomes were evaluated.Results4381 COVID-19 PCR tests were performed pre-procedurally during the study period, of which 18 (0.4%) were positive. Summary of characteristics is presented in Table 1. Mean age was 49.7 years, and the majority were female (61%) and black (67%). Six (33%) of 18 surgeries were performed despite positive COVID-19 PCR as shown in Table 2. Of those who had the procedure performed, none developed symptoms within 14 days. Two (11%) patients developed symptoms within 14 days of positive PCR after their procedures were canceled. None of those who had their procedure delayed developed any symptoms. Of the total patients, none required hospitalization or died.Table 1. Characteristics of asymptomatic patients with COVID-19 infection Table 2. Outcome of procedure in asymptomatic patients with COVID-19 ConclusionThe prevalence of COVID-19 infection was very low in our asymptomatic patient population. Decisions around SARS-CoV-2 testing in asymptomatic patients undergoing procedures should be based on exposure history and prevalence of disease in the community to avoid unnecessary testing and diversion of resources away from symptomatic patients.Disclosures All Authors: No reported disclosures

Prevalence of Cryptococcal Antigen and Outcomes in People With Human Immunodeficiency Virus in Honduras: A Cohort Study.

BackgroundCryptococcal meningitis is a major cause of death among people with human immunodeficiency virus (PWH). Cryptococcal antigen (CrAg) testing of asymptomatic patients is an important public health measure to reduce mortality in high-incidence areas. However, limited data exist on CrAg prevalence in Central America.MethodsWe conducted a prospective cohort study at the 2 largest human immunodeficiency virus (HIV) clinics and hospitals in Honduras. Cryptococcal antigen in serum and cerebrospinal fluid was performed in individuals with HIV who had CD4 ≤100 cells/mm3 between 2017 and 2018. After CrAg testing, individuals were observed for 12 months to assess mortality using adjusted Cox proportional hazard models.ResultsA total of 220 PWH were tested for CrAg, 12.7% (n = 28) of which tested positive. Cryptococcal antigen prevalence was higher among hospitalized individuals in 40% (n = 10 of 25) of the cases. The proportion (35.8%) of individuals taking antiretroviral therapy was significantly (P < .01) lower among those who tested positive for CrAg. Overall mortality among the cohort was 11.4% (n = 25 of 220) by 12 months. Cryptococcal antigen-positive cases were at a significantly higher risk of death (adjusted hazard ratio, 2.69; 95% confidence interval, 1.07–6.84) compared with CrAg-negative participants.ConclusionsCryptococcal antigen prevalence in Honduras was high among PWH. Moreover, individuals who tested positive for CrAg testing were at a higher risk of death. Systemic CrAg of PWH with a CD4 ≤100 cells/mm3 should be routinely performed in Central America.

Epiphyseal lymphoid infiltrates of the knee in adolescents.

We present three adolescents with focal lesions of the distal femur that were shown to be benign aggregates of small lymphocytes and plasma cells of unknown origin. The patients were within the age of 12 and 14years. All lesions presented with similar MRI findings and provided the same histopathological findings in the biopsy. Although all lesions increased in size, only one patient remained symptomatic and underwent subsequent tumor resection. To our best knowledge, tumor or pseudotumoral epiphyseal lymphoid infiltrates as seen in these three patients have not previously been described. We recommend a biopsy to rule out a malignant tumor or an infection. Observation, without further invasive testing in asymptomatic patients, is recommended until the resolution of the lesions. However, if a lesion becomes symptomatic, surgical resection should be considered.

UNIVERSAL SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING IN A NEW YORK CITY REPRODUCTIVE MEDICINE PRACTICE

To describe our single-center experience and results of universal SARS-CoV-2 testing in asymptomatic patients undergoing controlled ovarian hyperstimulation (COH). Retrospective cohort study conducted at a university-affiliated center. On March 21, 2020, New York-Presbyterian Hospital, where our retrieval suite is located, instituted a policy of universal SARS-CoV-2 testing prior to surgical procedures requiring anesthesia. As a result, we began testing all patients undergoing COH for SARS-CoV-2 using reverse transcription-polymerase chain reaction via nasopharyngeal swabs (Roche Cobas 6800). Tests were performed on the morning of cycle start and repeated 24 hours before oocyte retrieval. A positive test at either time point excluded patients from continuing with treatment. During the testing period, all patients and staff were required to wear surgical masks at all times when at our center and consented to symptom and temperature screening at every monitoring visit. Between March 21 and May 20, 2020, 169 asymptomatic patients underwent nasopharyngeal swabs at cycle start, four of which returned positive for SARS-CoV-2 for a center prevalence of 2.4%. All four patients were asymptomatic at the time of cycle start and were not permitted to begin their COH cycle. One of these patients had previously had a positive PCR swab over 60 days prior and had been symptom-free during this interval. One patient with a negative PCR swab on cycle start subsequently converted to positive 15 days later on her PCR swab prior to retrieval, despite the absence of COVID-19 symptoms. Per our hospital policy, she was not allowed to proceed with oocyte retrieval and was started on a course of daily GnRH antagonist and asked to abstain from intercourse for 14 days. None of the 5 patients went on to develop COVID-19 symptoms following their positive test result. All patients were referred to follow-up with their primary care provider. Prior to returning for further COH treatment, all patients will be required to undergo repeat PCR testing with a negative result. While rare, asymptomatic carriers of the SARS-CoV-2 virus were identified for a center prevalence of 2.4% in patients undergoing COH. Despite initial negative PCR testing, patients may convert to positive over the course of a COH cycle and not demonstrate symptoms. Strict personal protective equipment and social distancing use is essential to protect patients and staff alike.

Survey on the use of personal protective equipment and COVID-19 testing of pregnant women in Japan.

AimTo clarify the status of personal protective equipment (PPE) and coronavirus disease 2019 (COVID‐19) tests for pregnant women, we conducted an urgent survey.MethodsThe survey was conducted online from April 27 to May 1, 2020. Questionnaires were sent to core facilities and affiliated hospitals of the obstetrics and gynecology training program and to hospitals of the national perinatal medical liaison council.ResultsA total of 296 institutions participated in our survey; however, 2 institutions were excluded. Full PPE was used by doctors in 7.1% of facilities and by midwives in 6.8%. Our study also determined that around 65.0% of facilities for doctors and 73.5% of facilities for midwives used PPE beyond the “standard gown or apron, surgical mask, goggles or face shield” during labor of asymptomatic women. N95 masks were running out of stock at 6.5% of the facilities and goggles and face shields at 2.7%. Disposable N95 masks and goggles or face shields were re‐used after re‐sterilization in 12% and 14% of facilities, respectively. Polymerase chain reaction (PCR) testing of asymptomatic patients was performed for 9% of vaginal deliveries, 14% of planned cesarean sections and 17% of emergency cesarean sections. The number of PCR tests for obstetrics and gynecology per a week ranged from zero to five in 92% of facilities.ConclusionThe shortage of PPE in Japan is alarming. Sufficient stockpiling of PPE is necessary to prevent unnecessary disruptions in medical care. Appropriate guidelines for PPE usage and COVID‐19 testing of pregnant women at delivery are needed in Japan.

Delivering Dialysis During the COVID-19 Outbreak: Strategies and Outcomes

Abstract Background Haemodialysis (HD) patients are at increased risk of COVID-19 infection. Although all dialysis patients meet government criteria for shielding, only those on home treatment can comply. Patients attending incentre HD units represent a large and vulnerable group, who are unable to rigorously adhere to this advice. The need to adopt strategies to protect these patients is of great importance. We report our experience of delivering dialysis during the COVID-19 outbreak, describing the interventions taken to try to protect patients from virus transmission whilst maintaining optimal treatment. Methods We implemented measures, including use of; a system of active triage and isolation of suspected cases, separate transportation, a dedicated COVID-19 HD unit, personal protective equipment, active repatriation of patients back to base units. We collected data from all COVID-19 positive HD patients in our cohort, between 14/03/2020 - 20/04/2020. Data were compared to national reports of other units, and values obtained from a dialysis-specific Susceptible-Infectious-Removed model which predicted the impact of COVID-19 on our cohort. Results Results showed 76/670 (11.3%) tested positive for COVID-19. The majority were male (61.8%) and from a minority background (61.8%). 7/76 (9.2%) patients died following infection. The model projections overestimated the incidence of COVID-19, 221 vs 76 total number of infections by 20/4/20. Our incidence of COVID-19 and mortality are lower compared to other units across London. Conclusion Implementation of measures to limit the spread of COVID-19, and optimise dialysis, could account for the low infection and mortality rates observed in our cohort of patients.